<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Allo-SCT with reduced-intensity conditioning (RIC) results in lower non-relapse mortality (NRM), but higher relapse rate than myeloablative conditioning (MAC) in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>/<z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>Novel regimens with intensive anti-leukemic activity, but with limited toxicity will be of benefit </plain></SENT>
<SENT sid="2" pm="."><plain>In <z:hpo ids='HP_0000001'>all</z:hpo>, 85 patients with <z:e sem="disease" ids="C1332153" disease_type="Neoplastic Process" abbrv="">AML/MDS</z:e>, not eligible for MAC, were given fludarabine-treosulfan conditioning (FT) </plain></SENT>
<SENT sid="3" pm="."><plain>Outcomes were compared with those in patients given fludarabine-BU RIC (FB2, n=106) or reduced-toxicity (RTC) conditioning (FB4, fludarabine and myeloablative BU dose, n=85) </plain></SENT>
<SENT sid="4" pm="."><plain>The 5-year NRM was 29%, 20% and 18% after FT, FB2 and FB4, respectively (P=NS) </plain></SENT>
<SENT sid="5" pm="."><plain>Multivariate analysis (MVA) identified comorbidity score (HCT-CI) &gt;2 and advanced disease as adverse factors with no independent impact of regimen </plain></SENT>
<SENT sid="6" pm="."><plain>The 5-year relapse rate was 36%, 47% and 40%, respectively (P=0.17) </plain></SENT>
<SENT sid="7" pm="."><plain>MVA identified advanced disease as the major adverse factor, while FT had significantly lower relapse rate (hazard ratio 0.6, P=0.03) </plain></SENT>
<SENT sid="8" pm="."><plain>The 5-year survival (OS) was 37% with advanced disease </plain></SENT>
<SENT sid="9" pm="."><plain>HCT-CI &gt;2 and age â‰¥ 50 were found as adverse factors </plain></SENT>
<SENT sid="10" pm="."><plain>The 5-year OS was 46%, 44% and 50% after FT, FB2 and FB4 in early-intermediate-stage disease (P=NS) and 33%, 9% and 28% in advanced disease, respectively (P=0.02) </plain></SENT>
<SENT sid="11" pm="."><plain>FT is an RTC regimen with intensive anti-<z:hpo ids='HP_0001909'>leukemia</z:hpo> effect in MAC non-eligible patients </plain></SENT>
</text></document>